Multiple myeloma is a type of blood cancer that affects plasma cells, a kind of white blood cell found in the bone marrow. These cells normally help fight infections by producing antibodies.

In this study, co-led by N2CR member Prof Chng Wee Joo and team, which also includes N2CR member Dr Zhou Jianbiao, the researchers investigate how super enhancer (SE)-driven expression of SMC4 contributes to the progression of multiple myeloma (MM). SMC4 promotes cancer progression by activating the IFI16-STING signaling pathway, leading to increased production of pro-inflammatory cytokines. This creates a tumour-supportive microenvironment that enhances myeloma cell survival and proliferation. Inhibiting this pathway suppresses SMC4-driven oncogenic effects, suggesting a potential therapeutic target.

Click here to read more.